CJC-1295 with DAC has one of the longest documented half-lives among growth hormone-releasing peptides, at approximately 5.8–8.1 days in humans. CJC-1295 without DAC, on the other hand, has no published dedicated human half-life study. Understanding this difference explains almost everything else about how these two versions are used and discussed differently.
The half-life of CJC-1295 is approximately 5 to 7 days.
Half-life refers to the time it takes for half of a given dose of a substance to be eliminated from the bloodstream. This is a central concept for understanding how often a compound needs to be dosed to maintain a consistent effect. For CJC-1295 with DAC – a version that has been directly studied in human trials – researchers measured a half-life of approximately 5.8–8.1 days, following single escalating doses in healthy adults. This number comes from standard pharmacokinetic analysis within that study [1]. This is an extremely long half-life for a peptide. It exists specifically due to the DAC (Drug Affinity Complex) modification. This allows the peptide to form a covalent bond with serum albumin, the most abundant protein in the blood. This bond protects it from rapid degradation and renal filtration, which would otherwise clear it from circulation within minutes or hours [2].
For CJC-1295 without DAC, no dedicated human pharmacokinetic study measuring its half-life has been identified in the peer-reviewed literature reviewed for this article. As this version completely lacks the albumin binding mechanism, its half-life would be expected – based on structural similarity to native growth hormone-releasing hormone – to be measured in minutes rather than days. However, this is a reasonable conclusion drawn from chemistry rather than a number confirmed by a dedicated clinical study of the compound without DAC itself. This distinction should not be presented as an established fact.
CJC-1295 DAC Half-Life - Why Does It Matter?
The practical importance of CJC-1295 DAC's multi-day half-life becomes clear when one looks at how it was actually utilized in the human study that established it. Because the compound persists in the bloodstream for days rather than hours, the study's dosing schedules for repeated administration utilized weekly or bi-weekly injections, rather than daily dosing. This schedule was sufficient to elicit a cumulative effect on IGF-1, with levels remaining elevated for up to 28 days after a short series of doses [1]. This directly relates to why CJC-1295 DAC is frequently described in research and commercial contexts as a „long-acting” compound. A half-life measured in days means that the substance does not need to be re-introduced frequently in order to maintain elevated hormonal activity. This is a fundamentally different dosing logic than that of compounds cleared within minutes.
It's worth being precise about something here. This long half-life describes how long the peptide itself remains present and detectable in the blood. It does not mean that growth hormone or IGF-1 levels remain at peak for the entire duration. Separate studies have shown that even during this sustained presence of CJC-1295, the body's natural pulsatile pattern of growth hormone release continued. The main change was a significantly elevated baseline between pulses, rather than a flat, continuously elevated level [3].
How long does CJC-1295 stay in the body?
Placing the half-life of CJC-1295 in context alongside a related, better-known compound helps illustrate how remarkable its pharmacokinetic profile is. Sermorelin is an earlier and structurally related analog of GHRH. It was previously FDA-approved for diagnostic use in growth hormone deficiency. It has a well-documented half-life in humans of just about 11–12 minutes, after intravenous or subcutaneous administration. This is derived from pharmacokinetic data summarized in a peer-reviewed review of growth hormone secretagogues [4]. This means that CJC-1295 with DAC remains active in the body approximately 700–1000 times longer than sermorelin. This difference is entirely attributable to the albumin-binding modification of DAC, and not to any change in the base amino acid sequence common to both compounds.
Regarding how long CJC-1295 might be detectable by specialized doping control laboratory testing, as opposed to how long it remains pharmacologically active, this is a related but distinct question. This was discussed in an earlier article in this series concerning legal status and detectability. Peer-reviewed analytical chemistry studies have developed methods capable of detecting CJC-1295 in urine at concentrations at or below 1 nanogram per milliliter. However, it is worth noting that no single, universal „days since last dose” detection window has been established in the literature specifically for either the DAC or non-DAC form [5].
Limitations of current evidence
The half-life of CJC-1295 with DAC—5.8–8.1 days—is well-documented in a pivotal human pharmacokinetic study of the compound [1]. No equivalent dedicated human pharmacokinetic study for CJC-1295 without DAC has, however, been identified in the literature reviewed here. This means any specific half-life figure provided for the non-DAC form elsewhere should be treated as a chemical inference rather than a confirmed clinical finding.
Comparisons with sermorelin's half-life are well supported by separate, well-documented pharmacokinetic data [4]. This article, however, does not extend this comparison to dosing recommendations. As discussed in earlier articles in this series, no validated consumer dosing protocol exists for any form of CJC-1295.
Disclaimer
This content is for educational and informational purposes only and should not be interpreted as medical advice or as a dosing guide. CJC-1295, whether in its DAC or non-DAC form, is a research compound and is not approved by the FDA or European Medicines Agency for any medical use. The half-life data presented here for the DAC form are derived from a single published human pharmacokinetic study, and no equivalent human data exists for the non-DAC form. This information does not constitute a validated dosing schedule.
References
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[2] Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., van Wyk, P., Pham, K., & Bridon, D. P. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052–3058. https://doi.org/10.1210/en.2004-1286
[3] Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. https://doi.org/10.1210/jc.2006-1702
[4] Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., & von Haehling, S. (2020). Growth hormone secretagogues: History, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25–37. https://doi.org/10.1002/rco2.9
[5] Memdouh, S., Gavrilović, I., Ng, K., Cowan, D., & Abbate, V. (2021). Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis, 13(11–12), 1871–1887. https://doi.org/10.1002/dta.3183